Related Experiment Video
Updated: May 25, 2026
09:30
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
Clopidogrel and genetic testing: is it necessary for everyone?
Sweta Goswami1, Angela Cheng-Lai, James Nawarskas
1Department of Pharmacy, Jack D. Weiler Hospital of the Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA.
Cardiology in Review
|February 2, 2012
Summary
Clopidogrel efficacy varies due to CYP2C19 gene variations, impacting patients with atherothrombotic diseases. Genetic testing is available, but treatment adjustments based on results require further study.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Clinical Pharmacology
Background:
- Clopidogrel is a key antiplatelet medication for preventing atherothrombotic events.
- Concerns exist about clopidogrel's reduced efficacy in individuals with impaired drug metabolism, particularly 'poor metabolizers'.
- Genetic variations in the CYP2C19 enzyme are implicated in variable patient responses to clopidogrel.
Purpose of the Study:
- To review the impact of CYP2C19 genetic variations on clopidogrel efficacy.
- To discuss the implications of variable antiplatelet response for cardiovascular event risk.
- To examine the current status of genetic testing and therapeutic strategies for clopidogrel.
Main Methods:
- Literature review of studies investigating clopidogrel response and CYP2C19 genetics.
- Analysis of Food and Drug Administration (FDA) warnings and recommendations.
- Discussion of the limitations and future directions in pharmacogenomic-guided therapy.
Main Results:
- CYP2C19 genetic variants are associated with altered clopidogrel metabolism and antiplatelet activity.
- Increased risk of adverse cardiovascular events in poor metabolizers is suggested but not definitively proven.
- Commercial genetic testing exists, but clinical guidelines for adjusting clopidogrel therapy based on results are lacking.
Conclusions:
- Significant variability in clopidogrel response exists, partly due to CYP2C19 genetics.
- Further research and clinical trials are needed to guide the integration of pharmacogenomics into antiplatelet therapy.
- Optimal strategies for adjusting clopidogrel treatment based on genetic profiles remain under investigation.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...